US2006154901A1PendingUtilityA1

Methods for treating ocular rosacea

56
Individually held — no corporate assignee on recordPriority: May 8, 1998Filed: Dec 7, 2005Published: Jul 13, 2006
Est. expiryMay 8, 2018(expired)· nominal 20-yr term from priority
Inventors:Stephen C. PflugfelderBalakrishna L. LokeshwarMarie Selzer
A61P 7/02A61P 27/00A61P 33/00A61K 31/65A61P 27/02A61P 31/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of a CMT is also disclosed as part of the method for treating meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion.

Claims

exact text as granted — not AI-modified
1 - 27 . (canceled)  
     
     
         28 . A method of treating a patient suffering from ocular rosacea, said method comprising topically administering an effective, non-antimicrobial amount of tetracycline to an eye of said patient suffering from ocular rosacea.  
     
     
         29 . The method of  claim 28 , wherein said amount decreases inflammation on the ocular surface, in meibomian glands, or decreases the level of an inflammatory cytokine in aqueous tears.  
     
     
         30 . The method of  claim 29 , wherein said cytokine is interleukin-1-alpha.  
     
     
         31 . The method of  claim 28 , wherein said tetracycline is oxytetracycline.  
     
     
         32 . The method of  claim 28 , wherein said tetracycline is doxycycline.  
     
     
         33 . The method of  claim 28 , wherein said tetracycline is minocycline.  
     
     
         34 . The method of  claim 28 , wherein said treatment increases tear clearance in the eye of the patient.  
     
     
         35 . The method of  claim 28 , wherein said treatment comprises inhibiting a member selected from the group consisting of: matrix metalloproteinase activity in tear fluid, synthesis and activation of interleukin-1β, conversion of precursor interleukin-1β to mature interleukin-1β, ocular surface inflammation and reactive oxygen species in tear fluid and ocular surface epithelium.  
     
     
         36 . The method of  claim 35 , wherein said matrix metalloproteinase comprises matrix metalloproteinase-9.  
     
     
         37 . The method of  claim 28 , wherein said treatment comprises increasing production of interleukin-1 receptor antagonist by corneal epithelium.  
     
     
         38 . A method of treating a patient suffering from ocular rosacea, said method comprising orally administering an effective, non-antimicrobial amount of tetracycline to said patient suffering from ocular rosacea.  
     
     
         39 . The method of  claim 38 , wherein said amount decreases inflammation on the ocular surface, in meibomian glands, or decreases the level of an inflammatory cytokine in aqueous tears.  
     
     
         40 . The method of  claim 39 , wherein said cytokine is interleukin-1-alpha.  
     
     
         41 . The method of  claim 38 , wherein said tetracycline is oxytetracycline.  
     
     
         42 . The method of  claim 38 , wherein said tetracycline is doxycycline.  
     
     
         43 . The method of  claim 38 , wherein said tetracycline is minocycline.  
     
     
         44 . The method of  claim 38 , wherein said treatment increases tear clearance in the eye of the patient.  
     
     
         45 . The method of  claim 38 , wherein said treatment comprises inhibiting a member selected from the group consisting of matrix metalloproteinase activity in tear fluid, synthesis and activation of interleukin-1β, conversion of precursor interleukin-1β to mature interleukin-1β, ocular surface inflammation and reactive oxygen species in tear fluid and ocular surface epithelium.  
     
     
         46 . The method of  claim 45 , wherein said matrix metalloproteinase comprises matrix metalloproteinase-9.  
     
     
         47 . The method of  claim 38 , wherein said treatment comprises increasing production of an interleukin-1 receptor antagonist by corneal epithelium.  
     
     
         48 . A method of treating a patient suffering from ocular rosacea, said method comprising topically administering an effective amount of a non-antimicrobial tetracycline to an eye of said patient suffering from ocular rosacea.  
     
     
         49 . The method of  claim 48 , wherein said amount decreases inflammation on the ocular surface, in meibomian glands, or decreases the level of an inflammatory cytokine in aqueous tears.  
     
     
         50 . The method of  claim 49 , wherein said cytokine is interleukin-1-alpha.  
     
     
         51 . The method of  claim 48 , wherein said non-antimicrobial tetracycline is a tetracycline which lacks a dimethylamino side chain at position 4.  
     
     
         52 . The method of  claim 48 , wherein said non-antimicrobial tetracycline is a member selected from the group consisting of: 4-dedimethylaminotetracycline, 4-dedimethylamino-5-oxytetracycline, 4-dedimethylamino-7-chlorotetracycline, 4-hydroxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12a-deoxytetracycline, 4-dedimethylamino-11-hydroxy-12a-deoxytetracycline, 4-dedimethylamino-7-dimethylaminotetracycline, 6-dimethyl-6-deoxy-4-dedimethylaminotetracycline, 6-o-deoxy-5-hydroxy-4-dedimethylaminotetracycline, 11a-chlortetracycline, 12a-deoxytetracycline and 2-nitrilo analogs of tetracycline.  
     
     
         53 . The method of  claim 48 , wherein said treatment increases tear clearance in the eye of the patient.  
     
     
         54 . The method of  claim 48 , wherein said treatment comprises inhibiting a member selected from the group consisting of matrix metalloproteinase activity in tear fluid, synthesis and activation of interleukin-1β, conversion of precursor interleukin-1β to mature interleukin-1β, ocular surface inflammation and reactive oxygen species in tear fluid and ocular surface epithelium.  
     
     
         55 . The method of  claim 54 , wherein said matrix metalloproteinase comprises matrix metalloproteinase-9.  
     
     
         56 . The method of  claim 48 , wherein said treatment comprises increasing production of an interleukin-1 receptor antagonist by corneal epithelium.  
     
     
         57 . A method of treating a patient suffering from ocular rosacea, said method comprising orally administering an effective amount of a non-antimicrobial tetracycline to said patient suffering from ocular rosacea.  
     
     
         58 . The method of  claim 57 , wherein said amount decreases inflammation on the ocular surface, in meibomian glands, or decreases the level of an inflammatory cytokine in aqueous tears.  
     
     
         59 . The method of  claim 58 , wherein said cytokine is interleukin-1-alpha.  
     
     
         60 . The method of  claim 57 , wherein said non-antimicrobial tetracycline is a tetracycline which lacks a dimethylamino side chain at position 4.  
     
     
         61 . The method of  claim 57 , wherein said non-antimicrobial tetracycline is a member selected from the group consisting of: 4-dedimethylaminotetracycline, 4-dedimethylamino-5-oxytetracycline, 4-dedimethylamino-7-chlorotetracycline, 4-hydroxy-4-dedimethylaminotetracycline, 4-dedimethylamino-12a-deoxytetracycline, 4-dedimethylamino-11-hydroxy-12a-deoxytetracycline, 4-dedimethylamino-7-dimethylaminotetracycline, 6-dimethyl-6-deoxy-4-dedimethylaminotetracycline, 6-o-deoxy-5-hydroxy-4-dedimethylaminotetracycline, 11a-chlortetracycline, 12a-deoxytetracycline and 2-nitrilo analogs of tetracycline.  
     
     
         62 . The method of  claim 57 , wherein said treatment increases tear clearance in the eye of the patient.  
     
     
         63 . The method of  claim 57 , wherein said treatment comprises inhibiting a member selected from the group consisting of matrix metalloproteinase activity in tear fluid, synthesis and activation of interleukin-1β, conversion of precursor interleukin-1β to mature interleukin-1β, ocular surface inflammation and reactive oxygen species in tear fluid and ocular surface epithelium.  
     
     
         64 . The method of  claim 63 , wherein said matrix metalloproteinase comprises matrix metalloproteinase-9.  
     
     
         65 . The method of  claim 57 , wherein said treatment comprises increasing production of an interleukin-1 receptor antagonist by corneal epithelium.

Join the waitlist — get patent alerts

Track US2006154901A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.